Optimal dose of perineural dexamethasone for the prolongation of analgesia for peripheral nerve blocks: protocol for a systematic review and meta-analysis

• Published in: BMJ open Vol. 13; no. 7; p. e072598
• Main Authors: Chai, Wenjie, Wang, Shaopeng, Zhang, Donghang
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 19.07.2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Protocol
• Subjects: Adult; adult anaesthesia; Anaesthesia; Analgesia - methods; Analgesics; Anesthesia; Bias; Child; clinical pharmacology; Clinical trials; Dexamethasone; Drug dosages; Humans; Meta-analysis; Meta-Analysis as Topic; Pain; pain management; Patients; Pediatrics; Peripheral Nerves; Retrospective Studies; Steroids; Surgery; Systematic review; Systematic Reviews as Topic; adult anaesthesia; clinical pharmacology; pain management
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2023-072598

IntroductionPerineural use of dexamethasone is demonstrated to extend the analgesia duration of peripheral nerve blocks (PNB), but its optimal dose remains unclear. This systematic review and meta-analysis aims to determine the optimal dose of perineural dexamethasone in the prolongation of analgesia for PNB.Methods and analysisPubMed, EMBASE, the Cochrane Central Register of Controlled Trials and Web of Science will be searched from their inception to 1 March 2023. Language will be restricted to English. Randomised controlled trials that compared the efficacy and safety of different doses of perineural dexamethasone for PNB in adult patients will be included. Retrospective studies, reviews, meta-analyses, case reports, conference abstracts, comments and studies regarding paediatric surgeries will be excluded. The duration of analgesia will be defined as the primary outcome. Secondary outcomes will include pain scores, the total analgesic requirement over 48 hours and the incidence of adverse effects. Two reviewers will independently perform the study selection, data extraction and quality assessment. RevMan V.5.3 software will be used for data analysis. The quality of evidence will be assessed using the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) approach.Ethics and disseminationNo ethical approval is required. The results of this study will be submitted to peer-reviewed journals.PROSPERO registration numberCRD42022385672.